Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84


Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.

König L, Kasimir-Bauer S, Bittner AK, Hoffmann O, Wagner B, Santos Manvailer LF, Kimmig R, Horn PA, Rebmann V.

Oncoimmunology. 2017 Sep 27;7(1):e1376153. doi: 10.1080/2162402X.2017.1376153. eCollection 2017.


Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.

Kasimir-Bauer S, Bittner AK, König L, Reiter K, Keller T, Kimmig R, Hoffmann O.

Breast Cancer Res. 2016 Feb 12;18(1):20. doi: 10.1186/s13058-016-0679-3.


The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients.

König L, Kasimir-Bauer S, Hoffmann O, Bittner AK, Wagner B, Manvailer LF, Schramm S, Bankfalvi A, Giebel B, Kimmig R, Horn PA, Rebmann V.

Hum Immunol. 2016 Sep;77(9):791-9. doi: 10.1016/j.humimm.2016.01.002. Epub 2016 Jan 12.


Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.


Molecular characterization and heterogeneity of circulating tumor cells in breast cancer.

Jakabova A, Bielcikova Z, Pospisilova E, Matkowski R, Szynglarewicz B, Staszek-Szewczyk U, Zemanova M, Petruzelka L, Eliasova P, Kolostova K, Bobek V.

Breast Cancer Res Treat. 2017 Dec;166(3):695-700. doi: 10.1007/s10549-017-4452-9. Epub 2017 Aug 16.


Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.

Gu X, Xue JQ, Han SJ, Qian SY, Zhang WH.

Cancer Biomark. 2016;16(3):395-403. doi: 10.3233/CBM-160578.


Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.

Ušiaková Z, Mikulová V, Pintérová D, Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V, Kološtová K.

In Vivo. 2014 Jul-Aug;28(4):605-14.


Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function.

Aharon A, Sabbah A, Ben-Shaul S, Berkovich H, Loven D, Brenner B, Bar-Sela G.

Oncotarget. 2017 Jun 28;8(38):63265-63280. doi: 10.18632/oncotarget.18792. eCollection 2017 Sep 8.


Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis.

Levin C, Koren A, Rebibo-Sabbah A, Koifman N, Brenner B, Aharon A.

Front Physiol. 2018 Aug 30;9:1214. doi: 10.3389/fphys.2018.01214. eCollection 2018.


Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.

Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S552-8. doi: 10.1245/s10434-015-4600-6. Epub 2015 May 13.


Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients.

Cabinakova M, Mikulova V, Malickova K, Vrana D, Pavlista D, Petruzelka L, Zima T, Tesarova P.

Neoplasma. 2015;62(2):259-68. doi: 10.4149/neo_2015_031.


Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.

Singh LC, Chakraborty A, Mishra AK, Devi TR, Sugandhi N, Chintamani C, Bhatnagar D, Kapur S, Saxena S.

Med Oncol. 2012 Jun;29(2):539-46. doi: 10.1007/s12032-011-9952-6. Epub 2011 Apr 29.


Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.

Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.

Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29. Review.


Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer.

Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A.

Cancer. 2012 Jan 15;118(2):342-8. doi: 10.1002/cncr.26202. Epub 2011 Jun 29.


Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer.

Schwich E, Rebmann V, Horn PA, Celik AA, Bade-Döding C, Kimmig R, Kasimir-Bauer S, Buderath P.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1106. doi: 10.3390/cancers11081106.


Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.

Mikulová V, Cabiňaková M, Janatková I, Mestek O, Zima T, Tesařová P.

Scand J Clin Lab Invest. 2014 Mar;74(2):132-42. doi: 10.3109/00365513.2013.864784. Epub 2013 Dec 19.


Investigating the Potential and Pitfalls of EV-Encapsulated MicroRNAs as Circulating Biomarkers of Breast Cancer.

Moloney BM, Gilligan KE, Joyce DP, O'Neill CP, O'Brien KP, Khan S, Glynn CL, Waldron RM, Maguire CM, Holian E, Naughton E, Elhadi M, Grealish AB, Malone C, McDermott E, Dockery P, Ritter T, Prina-Mello A, Kerin MJ, Dwyer RM.

Cells. 2020 Jan 7;9(1). pii: E141. doi: 10.3390/cells9010141.


Changes of serum miR34a expression during neoadjuvant chemotherapy predict the treatment response and prognosis in stage II/III breast cancer.

Liu B, Su F, Li Y, Qi X, Liu X, Liang W, You K, Zhang Y, Zhang J.

Biomed Pharmacother. 2017 Apr;88:911-917. doi: 10.1016/j.biopha.2017.01.133. Epub 2017 Feb 6.


Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.

Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang HJ, Elashoff RM, Takeuchi H, Umetani N, Hoon DS.

J Clin Oncol. 2005 Nov 1;23(31):8057-64.


Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study.

Chintamani, Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P.

World J Surg Oncol. 2005 Sep 14;3:61.

Supplemental Content

Support Center